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Summary 
Background Control of HIV transmission could be achievable through an expansion of HIV testing of at-risk 
populations together with ready access and adherence to antiretroviral therapy. To examine whether increases in 
testing rates and antiretroviral therapy coverage correspond to the control of HIV transmission, we estimated HIV 
incidence in men who have sex with men (MSM) in England and Wales since 2001. 
Methods A CD4-staged back-calculation model of HIV incidence was used to disentangle the competing contributions 
of time-varying rates of diagnosis and HIV incidence to observed HIV diagnoses. Estimated trends in time to 
diagnosis, incidence, and undiagnosed infection in MSM were interpreted against a backdrop of increased HIV 
testing rates and antiretroviral-therapy coverage over the period 2001–10. 
Findings The observed 3·7 fold expansion in HIV testing in MSM was mirrored by a decline in the estimated mean 
time-to-diagnosis interval from 4·0 years (95% credible interval [CrI] 3·8–4·2) in 2001 to 3·2 years (2·6–3·8) by the 
end of 2010. However, neither HIV incidence (2300–2500 annual infections) nor the number of undiagnosed HIV 
infections (7370, 95% CrI 6990–7800, in 2001, and 7690, 5460–10 580, in 2010) changed throughout the decade, 
despite an increase in antiretroviral uptake from 69% in 2001 to 80% in 2010. 
Interpretation CD4 cell counts at HIV diagnosis are fundamental to the production of robust estimates of incidence based 
on HIV diagnosis data. Improved frequency and targeting of HIV testing, as well as the introduction of ART at higher CD4 
counts than is currently recommended, could begin a decline in HIV transmission among MSM in England and Wales. 
Funding UK Medical Research Council, UK Health Protection Agency. 
Introduction 
High levels of HIV testing combined with prompt 
antiretroviral therapy (ART) might substantially reduce 
HIV transmission, especially if high levels of engagement 
and retention in care can bring about a large reduction in 
community viral load (the aggregate viral load within a 
given population or risk group).1–4 Various models have 
investigated the eﬀ ect of diﬀ erent thresholds for the 
initiation of treatment, treatment uptake, and adherence 
rates and suggest that widespread ART coverage could 
have a population-level prevention eﬀ ect, thereby 
reducing HIV transmission.5–8 
Two studies of routinely collected surveillance data 
have shown an association between increases in ART 
coverage and declines in new HIV diagnoses and 
community viral load, one in British Columbia, Canada,3 
and another among men who have sex with men (MSM) 
in San Francisco, USA.1 The authors concluded that 
these results support the postulated secondary popu-
lation-level beneﬁ ts of ART. In England and Wales, MSM 
have the highest prevalence of HIV (9% in London and 
3% elsewhere).9 Most MSM are tested and diagnosed in 
free and conﬁ dential dedicated sexually transmitted 
infection (STI) clinics. Link to HIV care after diagnosis is 
prompt (more than 95% within 3 months)10 and retention 
in care is high (more than 95% a year).11 The initiation of 
ART is recommended in patients with a CD4 count 
below 350 cells per μL.12 New diagnoses in MSM have 
continued to rise over the past decade despite the high 
and rising coverage of ART. 
Although trends in new diagnoses remain a crucial 
measure of the HIV epidemic, they are a suboptimum 
measure of changes in HIV incidence.13 An HIV 
diagnosis is the outcome of three interacting processes: 
transmission, infection progression, and diagnosis. 
Consequently, the number of new diagnoses is a dynamic 
mixture of long-standing and recent infections, and is, 
therefore, not necessarily synonymous with the number 
of new infections. Only by reconstructing the complex 
mechanism underlying observed data can we disentangle 
the contribution of changes in testing patterns and in 
incidence to the recorded trends in HIV diagnoses and 
interpret them appropriately. We used a novel and simple 
CD4-staged back-calculation approach, incorporating 
CD4 counts at diagnosis and information on the natural 
history of HIV infection, to simultaneously estimate HIV 
incidence and trends in diagnosis rates in MSM in 
England and Wales for the decade 2001–10. From these 
estimated trends, we derived estimates of the number of 
undiagnosed infections over time and trends in the time 
from infection to diagnosis, giving additional insight into 
the eﬀ ect of HIV testing practices over the past decade. 
We present model outputs alongside comprehensive data 
for HIV testing rates and ART coverage to examine 
whether increases in testing rates and ART coverage in 
England and Wales have corresponded to the control of 
Lancet Infect Dis 2013; 
13: 313–18 
Published Online
February 1, 2013
http://dx.doi.org/10.1016/
S1473-3099(12)70341-9
See Comment page 279
 MRC Biostatistics Unit, 
Institute of Public Health, 
Cambridge, UK (P J Birrell PhD,  
D De Angelis PhD); and Health 
Protection Agency, Health 
Protection Services, London, 
UK (Prof O N Gill FFPH, 
V C Delpech FFPH, 
A E Brown PhD, S Desai MSc, 
T R Chadborn PhD, B D Rice MSc, 
D De Angelis)
Correspondence to: 
Dr Daniela De Angelis
MRC Biostatistics Unit, Institute 
of Public Health, University 
Forvie Site, Robinson Way, 
Cambridge CB2 0SR, UK 
daniela.deangelis@mrc-bsu.
cam.ac.uk 
Articles
314 www.thelancet.com/infection   Vol 13   April 2013
HIV transmission in MSM, where control is deﬁ ned as a 
sustained decline in incident HIV infections. 
Methods 
Data for the back-calculation model 
The model uses reports of new HIV and AIDS diagnoses 
and information on CD4 counts around diagnosis among 
MSM in England and Wales. Speciﬁ cally, the model uses 
quarterly aggregated counts of new AIDS-free and late 
HIV diagnoses from the early 1980s to the end of 2010. 
AIDS-free HIV diagnoses are those with no accompanying 
clinical AIDS diagnosis within 3 months, whereas a late 
HIV diagnoses refers to a clinical AIDS diagnosis that 
occurs before or within 3 months of HIV diagnosis. From 
1991, the national HIV database has been linked (using 
soundex code,14 date of birth, and sex)15 to CD4 count 
laboratory reports from haematology laboratories.16 From 
this linkage, data are available for the distribution of CD4 
counts at diagnosis. Here, a CD4 count is interpreted to be 
at diagnosis if it is the ﬁ rst recorded CD4 count for a 
patient taken within 3 months of their initial diagnosis. 
Between 1991 and 2010 these counts are available in 76% of 
all new diagnoses, rising to 91% in 2010. 
Other data sources 
Coverage of ART, deﬁ ned as the proportion of all people 
in HIV care who received ART at the date they were last 
seen, was obtained from the annual census of patients 
accessing care in all HIV outpatient services in England 
and Wales. Information relating to ART is complete for 
99% of patients.11,17 HIV testing data for MSM attending 
all STI clinics in England and Wales were extracted from 
quarterly clinic returns for the years 2001–10.18 
The high completeness of surveillance data is ensured 
through mutual supplementation of information between 
diﬀ erent systems; additionally, data are necessarily of 
high quality, because surveillance data directly inform the 
commissioning and funding of HIV services. Annual loss 
to follow-up rates for MSM accessing HIV care are very 
low (<5%).11  
The CD4 staged back-calculation HIV transmission 
model
The processes of infection, disease progression, and 
diagnosis of HIV-infected MSM are described through a 
discrete multistate model, with time steps every calendar 
quarter and disease states deﬁ ned by CD4 count and 
diagnosis status (appendix).19 After infection, transition 
between CD4 states is expressed through assumed known 
parameters representing the proportion of individuals 
progressing to the next CD4 state in each quarter, informed 
from the analysis of longitudinal CD4 counts in HIV-
infected people for whom the date of infection is well 
estimated.20 In each quarter, a CD4-speciﬁ c proportion of 
MSM is diagnosed. These proportions are allowed to vary 
over calendar time to reﬂ ect changing testing patterns 
throughout the epidemic. Using the data described above, 
the model permits the simultaneous estimation of HIV 
incidence and quarterly proportions diagnosed, from 
which we can quantify the changes in the time-to-diagnosis 
(appendix) and estimate the number of undiagnosed 
infections in each CD4 state, both with appropriate 
statements of uncertainty, expressed in terms of 95% 
credible intervals (CrI). 
Role of the funding source 
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results 
Between 2001 and 2010, the estimated number of new 
infections oscillated between 2200 and 2800 infections 
a year (ﬁ gure 1). Incidence increased to a peak in 2003–04, 
but, after a slight decline, stabilised at 2300–2500 infections 
a year from 2006 to the end of 2010. From 2007 onwards, 
the CrIs attached to the estimates of incidence are of 
steadily increasing width. This uncertainty arises because 
the data are less informative about the most recent 
infection numbers due to only a small proportion of these 
infections having had suﬃ  cient time to be diagnosed and 
thus appear in the data. However, there is no statistically 
signiﬁ cant change in incidence between any 2 years over 
the interval and no suggestion of an increasing or 
decreasing trend (see appendix). 
The proportion of undiagnosed individuals who are 
diagnosed each quarter from the two high CD4 count 
states (≥350 cells per μL) increased steadily over time 
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Figure 1: Annual numbers of new HIV infections for men who have sex with men in England and Wales
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(ﬁ gure 2), with a similar trend seen for the lower CD4 
counts (results not shown). As a result, the estimated 
snapshot time-to-diagnosis distributions (see appendix) 
indicate a trend towards earlier diagnosis over the decade 
(ﬁ gure 2). The mean time-to-diagnosis interval declined 
from 4·0 years (95% CrI 3·8–4·2) at the beginning of 2001 
to 3·2 years (2·6–3·8) by the end of 2010 (ﬁ gure 2). 
Furthermore, the total proportion of MSM diagnosed with 
a CD4 count greater than the recommended treatment 
threshold (≥350 cells per μL) increased from a low of 48% 
(45–52%) in the fourth quarter of 2001 to a high of 65% 
(57–74%) in the third quarter of 2010 (ﬁ gure 2B). Despite 
these developments, at 2010 rates of diagnosis, 38% of 
new infections will not be diagnosed until after the time at 
which they would have qualiﬁ ed for treatment (ﬁ gure 2). 
The estimated number of undiagnosed HIV infections 
increased steadily from the beginning of 2001 to a peak 
of 9140 (95% CrI 8720–9620) infections in the ﬁ rst 
quarter of 2005 (ﬁ gure 3). Since this time, there has been 
a quarter-on-quarter decline in the estimated number of 
undiagnosed infections, although, similarly to the 
estimation of incidence, these estimates, from 2007 
onwards, are characterised by increasing uncertainty. By 
the end of 2010 the estimated number of undiagnosed 
infections in MSM was 7690 (95% CrI 5460–10 580), 
similar to the 7370 (6990–7800) 10 years earlier. 
The estimated CD4 count distribution across the un-
diagnosed HIV infections has changed very gradually over 
time (ﬁ gure 3). Undiagnosed HIV infections with a CD4 
count of 500 cells per μL or higher consistently account for 
around 50% of the undiagnosed population, with the 
general trend following the number of incident infections 
in each year. These distributions contrast starkly with the 
observed CD4 count distributions at diagnosis, which are 
more evenly distributed across the CD4 count states, 
although diagnoses with CD4 counts higher than 500 cells 
per μL are still the most common (ﬁ gure 3). At the other 
end of the scale, the estimated number of undiagnosed 
HIV-infected MSM with a CD4 count of less than 350 cells 
per μL (and thus, in principle, eligible for treatment) 
remains unchanged from 1490 (95% CrI 1410–1570) at the 
start of 2001, to 1490 (1240–1770) at the end of 2010, 
although this change does represent a decrease from a 
peak in 2007 of 1790 (1700–1880) undiagnosed infections. 
These trends in HIV incidence and prevalence can be 
interpreted against contemporaneous data for uptake of 
ART, HIV tests done in STI clinics, and numbers of new 
HIV diagnoses among MSM (table). The annual number 
of new diagnoses rose from 1640 in 2001 to 2450 in 2005 
and levelled oﬀ  at around 2500 in 2010, whereas the 
number of men who presented with clinical AIDS at the 
time of their HIV diagnosis remained fairly stable (125 in 
2001 to 177 in 2010). The proportion of diagnoses 
occurring at high CD4 counts (≥500) has increased over 
the past 10 years, though not substantially (ﬁ gure 3). 
Around 16 000 men were tested for HIV in STI clinics in 
2001, a ﬁ gure that increased 3·7 fold over the decade 
to 59 300, a substantial growth in testing eﬀ ort (table). 
The number of HIV-diagnosed MSM receiving care rose 
steadily from 12 500 in 2001 to 27 900 in 2010, and the 
proportion receiving ART, already at 69% in 2001, 
increased to 80% in 2010. In 2001, 75% of MSM with a 
CD4 count of less than 350 cells per μL were in receipt of 
ART, compared with 84% in 2010. 
Discussion 
Our analysis of 20 years of a comprehensive population-
wide surveillance dataset using a CD4-based back-
calculation model shows that, over the past decade, there is 
no evidence of a decline in incidence among MSM, with 
new infections continuing at around 2300–2500 a year. 
Figure 2: Estimated trends in diagnosis by CD4 count
Proportions of HIV-infected MSM in each of the two high CD4 count states that are diagnosed per quarter (A). 
Estimated expected time to diagnosis and proportion diagnosed at CD4 count of more than 350 (B).  Lighter 
coloured lines indicate 95% credible interval.
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There is a signiﬁ cant declining trend in the estimated 
number of undiagnosed HIV infections between a peak at 
the end of 2004 to the end of 2008, and there is the 
suggestion that this trend may continue into 2010 
(ﬁ gure 3A), although the uncertainty attached to the most 
recent estimates makes this decrease diﬃ  cult to detect. By 
the end of 2010 we estimate that around 7700 MSM with 
HIV remained undiagnosed, corresponding to 22% of the 
total number of MSM with HIV, a decrease from 37% of 
the total number of infections in 2001. 
Our results conﬁ rm previous speculations about the 
high level of continuing HIV transmission in MSM and 
are consistent with earlier estimates of un diagnosed 
prevalence obtained using a multi para meter evidence 
synthesis approach, where a complex dynamic model is 
used to synthesise the information contained in several 
datasets.21,22 Over the past decade, the estimated 
diagnosed proportions from each CD4 state all steadily 
increased, resulting in a shortening of the mean time to 
diagnosis by 20% from 4·0 to 3·2 years. Through our 
back-calculation approach we estimated that, since 2001, 
the CD4 count of almost a third of the undiagnosed 
individuals was between 350 cells per μL and 500 cells 
per μL, and in half the count was above 500 cells per μL. 
Our modelling approach has several advantages. First, 
the model takes into account the interaction of three 
distinct processes (infection transmission, progression, 
and diagnosis), allowing the estimation of both rates of 
infection and diagnosis. Ignoring the propensity for 
individuals to be diagnosed, and temporal changes in this 
propensity, will lead to estimates for incidence that are 
based solely on CD4 cell counts and the natural history of 
HIV infection. Such estimates will typically be biased 
because of an over estimation of the time since infection as 
the time at risk of a diagnosis is completely ignored. 
Second, estimates of the number of undiagnosed 
infections in the various CD4 states are automatically 
generated and are consistent with the available 
information, without need for simplifying, untestable, 
assumptions (eg, similarity of the CD4 population proﬁ le 
of newly diagnosed and un diagnosed infections). Third, 
we use observed data from multiple sources, thus reducing 
the likelihood of biases that might be inherent in individual 
databases. Other researchers have also made use of 
multiple data sources, but they have referred to situations 
where, unlike here, there was no linkage between the new 
HIV and AIDS diagnoses,23 the data sources have been 
used independently with a comparison of the resulting 
estimates,24 or the additional data are simply used for 
model validation.25 Finally, the coherent, joint estimation of 
the time-varying incidence and diagnosis rates obtained 
through applying our back-cal culation method strengthens 
the argument that CD4 counts at diagnosis should be an 
integral part of national HIV surveillance systems. The 
availability and completeness of these data in new 
diagnoses databases in developed countries are poor.26
This work represents only the ﬁ rst step of a more 
comprehensive model, which could incorporate many 
more complexities (eg, a primary infection stage, or 
heterogeneity in risk behaviours), allowing the com-
prehensive investigation of scenarios that might explain 
the lack of transmission control. Some relevant ideas 
have already been explored in the analysis of the Dutch 
HIV epidemic.25 
In conclusion, although there is incontestable evidence 
regarding the beneﬁ ts of treatment as prevention at an 
individual level, there is no indication so far that the 
increased rates of testing and widened access to treatment 
have controlled HIV transmission in MSM in England and 
Wales (panel). The most plausible explanation for lack of 
HIV transmission control (ie, the lack of any sustained 
decline in incidence) during this period is a resurgence in 
unsafe sexual behaviour (largely because of treatment 
Figure 3: Undiagnosed infections and CD4 counts at diagnosis
Median numbers of undiagnosed infections among MSM in England and 
Wales (A). CD4 count among undiagnosed infections in MSM (B) and newly 
diagnosed infections (C).
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
0
2000
4000
6000
8000
10 000
12 000
A
N
um
be
r u
nd
ia
gn
os
ed
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
0
0·2
0·4
0·6
0·8
1·0
B
Pr
op
or
tio
n
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
0
0·2
0·4
0·6
0·8
1·0
C
Pr
op
or
tio
n
Year
CD4 ≥500 CD4 351–500 CD4 201–350 CD4 <200
Articles
www.thelancet.com/infection   Vol 13   April 2013 317
optimism),27 and in suﬃ  ciently frequent HIV testing 
among this population. The resurgence in unsafe sexual 
practices is evident through a concomitant epidemic of 
bacterial STIs and may have been ampliﬁ ed through social 
media accelerating wider partnership formation.18,28,29 
There is strong evidence of a multiple-fold increase over 
time in the numbers of HIV tests administered in STI 
clinics, the preferred facility for testing for 77% of high-risk 
MSM,30 and where 93% of MSM receive their initial HIV 
diagnosis (S Croxford, Health Protection Agency, personal 
communication). However, this increased testing eﬀ ort 
might not have suﬃ  ciently improved coverage of testing 
across the MSM population and the relatively modest 20% 
decrease in the estimated expected time-to-diagnosis and 
the 15% of diagnoses each year that seem to be clinically 
driven (diagnosis with a CD4 count of less than 200 cells 
per μL, ﬁ gure 3) would seem to conﬁ rm this. This 
improvement in diagnosis is certainly insuﬃ  cient to be 
able to capture a greater proportion of primary infections, 
which have been estimated to be responsible for up to 50% 
of transmission.31,32 
Treatment status and viral load are available for every 
patient in care in England and Wales, in which almost all 
diagnosed individuals are retained. By 2010, 80% of all 
diagnosed infections were being treated with antiretroviral 
therapy, rising to 84% in those with a CD4 count lower 
than 350 cells per μL. Recent evidence shows that around 
35% of patients, most of whom are not in receipt of 
treatment, have viral loads of greater than 1500 copies 
per mL and are therefore at risk of transmitting the 
infection.33 By contrast with the treatment cascade in the 
USA, where there is a lower retention in care, albeit with a 
higher proportion of these patients on antiretroviral 
therapy,34 our estimates of the number of undiagnosed 
MSM in England and Wales are higher than the observed 
number of diagnosed MSM who remain untreated (table). 
This ﬁ nding strongly suggests that the undiagnosed 
infections represent the principal part of the community 
viral load reservoir driving HIV transmission.35,36 
The ﬁ ndings in our paper should alert policy makers and 
public health authorities to the limited eﬀ ect of the national 
HIV Strategy (England),37 which aimed to reduce 
transmission through increasing the uptake of HIV testing 
in STI clinics, and to the fact that high antiretroviral 
coverage alone might not be suﬃ  cient to eliminate HIV 
transmission. Primary prevention and earlier, more 
targeted, testing must continue to be prioritised as part of 
any national HIV prevention plan. In view of the proﬁ le of 
CD4 counts in newly diagnosed patients, showing that 
around 60% are not immediately eligible for antiretroviral 
therapy, the initiation of treatment on diagnosis of HIV 
infection, irrespective of CD4 count, might well be 
necessary to achieve control of HIV transmission. To this 
extent, we welcome the new British HIV Association 
guidelines recommending that clinicians discuss the 
Panel: Research in context
Systematic review
A search of PubMed using (“antiretroviral therapy” OR “HIV testing”) AND (“HIV diagnoses” 
OR “HIV incidence” OR “HIV prevalence”) AND “HIV prevention” yielded 19 articles. We 
selected a subset of these articles, choosing those that investigated the (in some cases, 
potential) impact of expanded testing and/or treatment upon HIV incidence and that 
included a signiﬁ cant mathematical or statistical modelling component.1,3,5,7 These 
modelling studies were augmented by browsing related citations, identifying three further 
modelling studies.6,8,25 Since this is a highly active area of current research, further references 
came to our attention during the lifespan of this work.2,4,13 None of these studies were 
directly relevant to a health-care system like that of England and Wales, where HIV is 
hyperendemic, retention in care is high and treatment is prescribed to many HIV infected 
individuals with a CD4 count less than 350 cells per μL.
Interpretation
Using the rich array of HIV surveillance data available in England and Wales, we have adopted 
a novel, relatively parsimonious, CD4-based back-calculation model to estimate 
simultaneously HIV incidence and CD4-speciﬁ c diagnosis rates among MSM over the period 
2001–2010.19 Furthermore, this work results in the estimation of the number of undiagnosed 
infections by CD4 count. We did not ﬁ nd any clear evidence for declining incidence despite 
an estimated shortening of the time-to-diagnosis from 4·0 years to 3·2 years. The number of 
undiagnosed infections declined only slightly from the middle of the decade, returning to 
2001 levels. These results are set alongside data highlighting expanded testing eﬀ ort and 
greater treatment coverage over the period. Modelling studies have raised great enthusiasm 
for the potential of test-and-treat practices to provide control of HIV transmission.1–7 
However, a few studies have identiﬁ ed situations where such practices have only a modest or 
short-lived beneﬁ t and discuss their limitations.8,13,25 In this work we demonstrate how 
expanding testing and high (and rising) treatment coverage have not corresponded to a 
decline in HIV transmission. We suggest that healthcare services in England and Wales will 
need to provide more targeted testing of the at-risk population and to start treatment earlier 
if a sustained decline in HIV incidence is to be brought about. 
   2001  2002  2003  2004  2005  2006  2007  2008  2009  2010 
Total number of infected individuals in HIV care  12 529  13 834  15 354  17 028  18 877  20 762  22 683  24 342  26 061  27855 
Total number of infected individuals receiving ART  8643  10 029  10 622  11 695  12 866  14 731  15 907  18 150  19 999  22399 
Percentage of infected individuals in HIV care in receipt of ART  69%  72%  69%  69%  68%  71%  70%  75%  77%  80%  
Number of HIV tests in STI clinics  16 000  18 200  24 000  26 400  30 700  35 000  37 200  42 700  52 300  59 300 
New HIV diagnoses  1640  1780  1970  2240  2450  2440  2640  2470  2440  2550  
New HIV diagnoses presenting as AIDS  158  175  164  177  170  153  170  157  129  152  
ART=antiretroviral therapy. STI=sexually transmitted infection.
Table: Recent trends in the number of HIV-infected men who have sex with men in England and Wales
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beneﬁ ts of early treatment uptake as a prophylactic to 
protect sexual partners.12 
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